RYPLAZIM ® (plasminogen, human-tvmh) is a medicine used for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). RYPLAZIM is contraindicated in patients with known hypersensitivity to plasminogen or other components of RYPLAZIM.

RYPLAZIM is a plasma-derived human plasminogen replacement therapy formulated for IV administration and approved for use in PLGD-1 patients of all ages. RYPLAZIM raises plasminogen levels in the blood—the goal of treatment is to increase the levels by at least 10% from baseline. Viral safety starts with safe collection of plasma.

Ryplazim是一种血浆来源的人纤溶酶原，适用于治疗1型纤溶酶原缺乏症 (低胞浆素血症)患者。 【Ryplazim剂量和给药】 仅用于重建后的静脉内使用。 RYPLAZIM 的推荐剂量为每 2 至 4 天给予 6.6 毫克/千克体重。 【Ryplazim剂型和规格】 RYPLAZIM有单剂量50毫升小瓶装，含有68.8毫克纤溶酶原，作为 冻干粉，用12.5毫升无菌 注射用水，USP（SWFI）重新配制。 重新配制后，每个小瓶将含有5.5毫克/毫升纤溶酶原。 【Ryplazim禁忌症】 RYPLAZIM禁用于已知对纤溶酶原 …

RYPLAZIM (plasminogen, human-tvmh) is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).

值得一提的是， Ryplazim是FDA批准的第一个治疗纤溶酶原缺乏症的药物。 这是一种罕见的 遗传 性疾病，可损害正常组织和器官功能，并可能导致失明。

2024年5月13日 · RYPLAZIM is a medicine containing human plasminogen and is used to increase the blood levels of plasminogen in people with plasminogen deficiency type 1 (hypoplasminogenemia). It is injected into a vein. Who should not use RYPLAZIM? Do not take RYPLAZIM if you have had a severe reaction to RYPLAZIM or …

Liminal BioSciences公司近日宣布，美国食品和药物管理局（FDA）已批准Ryplazim（plasminogen, human-tvmh，人纤溶酶原），用于治疗1型纤溶酶原缺乏症（低纤溶酶原血症）患者。

2023年8月23日 · Ryplazim is a medicine containing human plasminogen and is used to increase the blood levels of plasminogen in people with plasminogen deficiency type 1 (hypoplasminogenemia). It is injected into a vein. Who should not use Ryplazim? You should not use Ryplazim if you have had a severe reaction to Ryplazim or …

2024年4月29日 · RYPLAZIM® is the first and only FDA-approved treatment for the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1). PLGD-1 is an ultra-rare disease that leads to reduced plasminogen activity levels in the body, often resulting in fibrinous lesions on various organs.

Ryplazim由Liminal Biosciences公司开发，于今年6月获得美国FDA批准， 是第一个治疗纤溶酶原缺乏症的药物。 值得一提的是，在批准Ryplazim的同时， FDA 还颁发给Liminal BioSciences公司一张罕见儿科疾病优先审查凭证（PRV），以奖励该公司在罕见病新药研发方面的突出贡献。 该券可以兑换以获得任何后续新药申请的优先审查，并且可以出售或转让。 今年10月，Kedrion完成收购Liminal Biosciences旗下血浆纯化工厂Prometic Biotherapeutics并获得在美国销售Ryplazim …